CIK 0001640266
- Accelerated filer
- Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-06 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2022-06-06 | Vitale Nancy Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2022-06-06 | PIERCE GLENN Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2022-04-04 | Swartz Robin Chief Operating Officer | Sale | −1,527 | $8.25 | $13K | 52,060 |
| 2022-04-04 | Hesslein Robert W. Senior VP & General Counsel | Sale | −2,786 | $8.25 | $23K | 114,963 |
| 2022-03-22 | Sandrock Alfred President and CEO | Grant or award | +100,000 | 100,000 | ||
| 2022-03-22 | Sandrock Alfred President and CEO | Grant or award · Stock Option (Right to Buy) | +940,600 | 940,600 | ||
| 2022-03-21 | Swartz Robin Chief Operating Officer | Sale | −4,362 | $8.29 | $36K | 53,638 |
| 2022-03-21 | Swartz Robin Chief Operating Officer | Sale | −51 | $8.68 | $443 | 53,587 |
| 2022-03-21 | Hesslein Robert W. Senior VP & General Counsel | Sale | −4,897 | $8.29 | $41K | 117,807 |
| 2022-03-21 | Hesslein Robert W. Senior VP & General Counsel | Sale | −58 | $8.68 | $503 | 117,749 |
| 2022-03-21 | Burek Julie VP, Finance | Sale | −2,618 | $8.29 | $22K | 52,489 |
| 2022-03-21 | Burek Julie VP, Finance | Sale | −31 | $8.68 | $269 | 52,458 |
| 2022-02-17 | Hesslein Robert W. Senior VP & General Counsel | Sale | −4,100 | $3.55 | $15K | 122,704 |
| 2022-02-17 | Burek Julie VP, Finance | Sale | −789 | $3.55 | $3K | 55,107 |
| 2022-02-11 | Hesslein Robert W. Senior VP & General Counsel | Sale | −3,252 | $3.36 | $11K | 126,804 |
| 2022-02-11 | Burek Julie VP, Finance | Sale | −361 | $3.36 | $1K | 55,896 |
| 2022-02-07 | Swartz Robin Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2022-02-07 | Sandrock Alfred Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2022-01-13 | Burek Julie VP, Finance | Grant or award | +10,000 | 56,257 |
Page 10 of 19 · 368 trades